To study effect of superior hypogastric plexus block for postoperative pain relief after hysterectomy in gynecological malignancies patients

Efficacy of intraoperative superior hypogastric plexus block for post operative analgesia after hysterectomy in gynecological malignancies- A Randomized Control Study - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/083848

Enrollment

Registered

2025-04-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C55- Malignant neoplasm of uterus, partunspecified Health Condition 2: C569- Malignant neoplasm of unspecifiedovary Health Condition 3: C539- Malignant neoplasm of cervix uteri, unspecified Health Condition 4: C549- Malignant neoplasm of corpus uteri, unspecified

Interventions

Intervention1: group A will recieve Superior hypogastric plexus block intraoperatively as well as transverse abdominis plane block before extubation.: females suffering from gynecological malignancie

Eligibility

Inclusion criteria

Inclusion criteria: ASA gradeIII Gynecological Malignancies i.e ovarian,endometrium,cervical

Exclusion criteria

Exclusion criteria: 1.Patient refusal 2.Allergic to Local anaesthetic agents. 3.Patient with major Cardiac and respiratory diseases 4.Coagulopathies 5.Patient with hepatic and renal dysfunction. 6.Patient having chronic pain due to other causes. 7.patient having significant bradycardia.

Design outcomes

Primary

Measure	Time frame
Duration of analgesia using VAS ScoreTimepoint: Duration of analgesia using VAS Score at 0,1,2,3,4,5,,6,8,10,12,24,48 hours	—

Secondary

Measure	Time frame
time to first rescue analgesia total dose of tramadol consumption post operative quality of recovery using QoR -15 Score at 24 hrs,1 week,1 month complication and adverse effects such as bradycardia, hypotension, bleeding, infections, allegic reactions to drugTimepoint: secondary outcome will be assesed at 24hrs,1 week and 1 month	—

Countries

India

Contacts

Public ContactDr Pratibha Jain Shah

Pt JNM Medical College Raipur

prati_jain@rediffmail.com9827276620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026